Clinical Trial Update: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant elacestrant versus standard endocrine therapy in high-risk ER+/HER2- breast cancer is currently not recruiting. The study is s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer, HR+/HER2- Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING